Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692803 · ClinicalTrials.gov registry record
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
A clinical trial of Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,043
- Enrollment target
- 1
- Study location
NCT06692803: Completed study of Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals.
NCT06692803 is a study of Chronic Myeloid Leukemia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,043 participants, above the 152-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (1244% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06692803, a study of Chronic Myeloid Leukemia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,043 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database. Adult patients newly diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) were identified using the Optum database and classified into the following cohorts: * First treatment cohort: Patients newly diagnosed with CML who received first treatment with a TKI. * Second treatment cohort: Patients from first treatment cohort with a subsequent line of therapy (i.e., second treatment) with a TKI. The observation period spanned from the start of data availability (i.e., 01 January 2007) to the earliest of end of data (i.e., 30 June 2022), end of continuous health plan enrollment, or death (if available). The index date was defined as the first treatment initiation for the first treatment TKI cohort and as the second treatment initiation for the second treatment TKI cohort. The baseline period consisted of the 6 months prior to the index date. The follow-up period started on the index date and ended at the earliest of end of observation period or hematopoietic stem cell transplantation (HSCT).
Primary Outcome
Tyrosine kinase inhibitor (TKI) treatment management patterns in CML patients on first line or second line TKI were assessed.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,043 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2023-11-30 |
What the finished NCT06692803 record still lists
NCT06692803 is an observational study that tracks outcomes without assigning an intervention. Its 2,043 participants enrollment target places it among the larger protocols in the corpus, above the 152-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (1244% higher).
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT06692803 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06692803 about?
NCT06692803 is a clinical study titled "Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy". This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database. Adult patients newly diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) were identified using the Optum database and class...
What is the current status of trial NCT06692803?
This trial is currently completed. The enrollment target is 2,043 participants. The study started on 2023-05-23. Estimated completion is 2023-11-30.
What conditions does trial NCT06692803 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
Who is sponsoring clinical trial NCT06692803?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692803 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06692803's enrollment target sits among peer trials
2,043 1st of 35 higher than 35 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Study of Olverembatinib (HQP1351) in Patients With CP-CML
RECRUITING · Phase 3
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI